|
1
|
Slominski RM, Sarna T, Płonka PM, Raman C,
Brożyna AA and Slominski AT: Melanoma, melanin, and melanogenesis:
The yin and yang relationship. Front Oncol.
12(842496)2022.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Slominski A, Tobin DJ, Shibahara S and
Wortsman J: Melanin pigmentation in mammalian skin and its hormonal
regulation. Physiol Rev. 84:1155–1228. 2004.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Videira IF, Moura DF and Magina S:
Mechanisms regulating melanogenesis. An Bras Dermatol. 88:76–83.
2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Garmyn M, Young AR and Miller SA:
Mechanisms of and variables affecting UVR photoadaptation in human
skin. Photochem Photobiol Sci. 17:1932–1940. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Slominski RM, Raman C, Chen JY and
Slominski AT: How cancer hijacks the Body's homeostasis through the
neuroendocrine system. Trends Neurosci. 46:263–275. 2023.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Wolf Horrell EM, Boulanger MC and D'Orazio
JA: Melanocortin 1 receptor: Structure, function, and regulation.
Front Genet. 7(95)2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Li C, Kuai L, Cui R and Miao X:
Melanogenesis and the targeted therapy of melanoma. Biomolecules.
12(1874)2022.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Kawaguchi M, Valencia JC, Namiki T, Suzuki
T and Hearing VJ: Diacylglycerol kinase regulates tyrosinase
expression and function in human melanocytes. J Invest Dermatol.
132:2791–2799. 2012.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Slominski A, Wortsman J, Mazurkiewicz JE,
Dietrich J, Lawrence K, Gorbani A and Paus R: Detection of
proopiomelanocortin-derived antigens in normal and pathologic human
skin. J Lab Clin Med. 122:658–666. 1993.PubMed/NCBI
|
|
10
|
Slominski A, Paus R and Mihm MC:
Inhibition of melanogenesis as an adjuvant strategy in the
treatment of melanotic melanomas: Selective review and hypothesis.
Anticancer Res. 18:3709–3715. 1998.PubMed/NCBI
|
|
11
|
Slominski A, Zmijewski MA and Pawelek J:
L-tyrosine and L-dihydroxyphenylalanine as hormone-like regulators
of melanocyte functions. Pigment Cell Melanoma Res. 25:14–27.
2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Huang AC and Zappasodi R: A decade of
checkpoint blockade immunotherapy in melanoma: Understanding the
molecular basis for immune sensitivity and resistance. Nat Immunol.
23:660–670. 2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020:
GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36
Cancers in 185 Countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kozovska Z, Gabrisova V and Kucerova L:
Malignant melanoma: Diagnosis, treatment and cancer stem cells.
Neoplasma. 63:510–517. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Luke JJ, Flaherty KT, Ribas A and Long GV:
Targeted agents and immunotherapies: Optimizing outcomes in
melanoma. Nat Rev Clin Oncol. 14:463–482. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Heistein JB and Acharya U: Malignant
Melanoma. StatPearls. Treasure Island (FL), StatPearls Publishing
Copyright ©. 2022, StatPearls Publishing LLC., 2022.
|
|
17
|
Steeb T, Wessely A, Petzold A, Kohl C,
Erdmann M, Berking C and Heppt MV: c-Kit inhibitors for
unresectable or metastatic mucosal, acral or chronically
sun-damaged melanoma: A systematic review and one-arm
meta-analysis. Eur J Cancer. 157:348–357. 2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
El Zaoui I, Bucher M, Rimoldi D, Nicolas
M, Kaya G, Pescini Gobert R, Bedoni N, Schalenbourg A, Sakina E,
Zografos L, et al: Conjunctival melanoma targeted therapy: MAPK and
PI3K/mTOR pathways inhibition. Invest Ophthalmol Vis Sci.
60:2764–2772. 2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou
J, Sasada T, Zeng W, Giobbie-Hurder A, Atkins MB, Ibrahim N, et al:
Bevacizumab plus ipilimumab in patients with metastatic melanoma.
Cancer Immunol Res. 2:632–642. 2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Wu X, Giobbie-Hurder A, Liao X, Lawrence
D, McDermott D, Zhou J, Rodig S and Hodi FS: VEGF Neutralization
Plus CTLA-4 blockade alters soluble and cellular factors associated
with enhancing lymphocyte infiltration and humoral recognition in
melanoma. Cancer Immunol Res. 4:858–868. 2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Andtbacka RH, Kaufman HL, Collichio F,
Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I,
Agarwala SS, et al: Talimogene laherparepvec improves durable
response rate in patients with advanced melanoma. J Clin Oncol.
33:2780–2788. 2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
McArthur GA, Chapman PB, Robert C, Larkin
J, Haanen JB, Dummer R, Ribas A, Hogg D, Hamid O, Ascierto PA, et
al: Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K
mutation-positive melanoma (BRIM-3): Extended follow-up of a phase
3, randomised, open-label study. Lancet Oncol. 15:323–332.
2014.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Overman MJ, Lonardi S, Wong KYM, Lenz HJ,
Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill
A, et al: Durable clinical benefit with nivolumab plus ipilimumab
in DNA mismatch repair-deficient/microsatellite instability-high
metastatic colorectal cancer. J Clin Oncol. 36:773–779.
2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Gerosa L, Chidley C, Fröhlich F, Sanchez
G, Lim SK, Muhlich J, Chen JY, Vallabhaneni S, Baker GJ, Schapiro
D, et al: Receptor-Driven ERK pulses reconfigure MAPK signaling and
enable persistence of Drug-Adapted BRAF-Mutant melanoma cells. Cell
Syst. 11:478–494.e9. 2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Tang KT and Lee CH: BRAF mutation in
papillary thyroid carcinoma: Pathogenic role and clinical
implications. J Chin Med Assoc. 73:113–1128. 2010.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Long GV, Stroyakovskiy D, Gogas H,
Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A,
Grob JJ, et al: Dabrafenib and trametinib versus dabrafenib and
placebo for Val600 BRAF-mutant melanoma: A multicentre,
double-blind, phase 3 randomised controlled trial. Lancet.
386:444–451. 2015.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Ascierto PA, Dréno B, Larkin J, Ribas A,
Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L,
et al: 5-Year outcomes with cobimetinib plus vemurafenib in
BRAFV600 Mutation-positive advanced melanoma: Extended Follow-up of
the coBRIM study. Clin Cancer Res. 27:5225–5235. 2021.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Hauschild A, Larkin J, Ribas A, Dréno B,
Flaherty KT, Ascierto PA, Lewis KD, McKenna E, Zhu Q, Mun Y and
McArthur GA: Modeled prognostic subgroups for survival and
treatment outcomes in BRAF V600-mutated metastatic melanoma: Pooled
analysis of 4 randomized clinical trials. JAMA Oncol. 4:1382–1388.
2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Dickson PV and Gershenwald JE: Staging and
prognosis of cutaneous melanoma. Surg Oncol Clin N Am. 20:1–17.
2011.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Larkin J, Ascierto PA, Dréno B, Atkinson
V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas
L, et al: Combined vemurafenib and cobimetinib in BRAF-mutated
melanoma. N Engl J Med. 371:1867–1876. 2014.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Gutzmer R, Stroyakovskiy D, Gogas H,
Robert C, Lewis K, Protsenko S, Pereira RP, Eigentler T, Rutkowski
P, Demidov L, et al: Atezolizumab, vemurafenib, and cobimetinib as
first-line treatment for unresectable advanced BRAFV600
mutation-positive melanoma (IMspire150): Primary analysis of the
randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet. 395:1835–1844. 2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Ascierto P, Robert C, Lewis K, Gutzmer R,
Stroyakovskiy D, Gogas HJ, Protsenko S, Pereira RP, Kurt Eigentler
T, Rutkowski P, et al: 1102P Clinical benefit in BRAFV600
mutation-positive melanoma defined by programmed death ligand 1
(PD-L1) and/or lactate dehydrogenase (LDH) status: Exploratory
analyses from the IMspire150 study. Ann Oncol. 31(S745)2020.
|
|
33
|
Dummer R, Queirolo P, Abajo Guijarro AM,
Hu Y, Wang D, de Azevedo SJ, Robert C, Ascierto PA, Chiarion-Sileni
V, Pronzato P, et al: Atezolizumab, vemurafenib, and cobimetinib in
patients with melanoma with CNS metastases (TRICOTEL): A
multicentre, open-label, single-arm, phase 2 study. Lancet Oncol.
23:1145–1155. 2022.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Tawbi HA, Forsyth PA, Algazi A, Hamid O,
Hodi FS, Moschos SJ, Khushalani NI, Lewis K, Lao CD, Postow MA, et
al: Combined Nivolumab and Ipilimumab in melanoma metastatic to the
brain. N Engl J Med. 379:722–730. 2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Davies MA, Saiag P, Robert C, Grob JJ,
Flaherty KT, Arance A, Chiarion-Sileni V, Thomas L, Lesimple T,
Mortier L, et al: Dabrafenib plus trametinib in patients with
BRAFV600-mutant melanoma brain metastases (COMBI-MB): A
multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol.
18:863–873. 2017.PubMed/NCBI View Article : Google Scholar
|
|
36
|
de la Cruz-Merino L, Di Guardo L, Grob JJ,
Venosa A, Larkin J, McArthur GA, Ribas A, Ascierto PA, Evans JTR,
Gomez-Escobar A, et al: Clinical features of serous retinopathy
observed with cobimetinib in patients with BRAF-mutated melanoma
treated in the randomized coBRIM study. J Transl Med.
15(146)2017.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Ribas A, Gonzalez R, Pavlick A, Hamid O,
Gajewski TF, Daud A, Flaherty L, Logan T, Chmielowski B, Lewis K,
et al: Combination of vemurafenib and cobimetinib in patients with
advanced BRAF(V600)-mutated melanoma: A phase 1b study. Lancet
Oncol. 15:954–965. 2014.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Grimaldi AM, Simeone E and Ascierto PA:
Vemurafenib plus cobimetinib in the treatment of mutated metastatic
melanoma: The CoBRIM trial. Melanoma Manag. 2:209–215.
2015.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Callahan MK and Chapman PB: PD-1 or PD-L1
blockade adds little to combination of BRAF and MEK inhibition in
the treatment of BRAF V600-mutated melanoma. J Clin Oncol.
40:1393–1395. 2022.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Long GV, Hauschild A, Santinami M,
Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M,
Dutriaux C, Haydon A, et al: Adjuvant dabrafenib plus trametinib in
stage III BRAF-mutated melanoma. N Engl J Med. 377:1813–1823.
2017.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Schadendorf D, Hauschild A, Santinami M,
Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M,
Dutriaux C, Haydon A, et al: Patient-reported outcomes in patients
with resected, high-risk melanoma with BRAFV600E or
BRAFV600K mutations treated with adjuvant dabrafenib
plus trametinib (COMBI-AD): A randomised, placebo-controlled, phase
3 trial. Lancet Oncol. 20:701–710. 2019.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Dummer R, Hauschild A, Santinami M,
Atkinson V, Mandalà M, Kirkwood JM, Chiarion Sileni V, Larkin J,
Nyakas M, Dutriaux C, et al: Five-year analysis of adjuvant
dabrafenib plus trametinib in stage III melanoma. N Engl J Med.
383:1139–1148. 2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Atkinson V, Robert C, Grob JJ, Gogas H,
Dutriaux C, Demidov L, Gupta A, Menzies AM, Ryll B, Miranda F, et
al: Improved pyrexia-related outcomes associated with an adapted
pyrexia adverse event management algorithm in patients treated with
adjuvant dabrafenib plus trametinib: Primary results of
COMBI-APlus. Eur J Cancer. 163:79–87. 2022.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Delord JP, Robert C, Nyakas M, McArthur
GA, Kudchakar R, Mahipal A, Yamada Y, Sullivan R, Arance A, Kefford
RF, et al: Phase I dose-escalation and -expansion study of the BRAF
inhibitor encorafenib (LGX818) in metastatic BRAF-mutant melanoma.
Clin Cancer Res. 23:5339–5348. 2017.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Dummer R, Ascierto PA, Gogas HJ, Arance A,
Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer
R, et al: Encorafenib plus binimetinib versus vemurafenib or
encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): A
multicentre, open-label, randomised phase 3 trial. Lancet Oncol.
19:603–615. 2018.PubMed/NCBI View Article : Google Scholar
|
|
46
|
O'Connor Mark J: Targeting the DNA damage
response in cancer. Mol Cell. 60:547–560. 2015.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Lieber MR: The mechanism of double-strand
DNA break repair by the nonhomologous DNA end-joining pathway. Annu
Rev Biochem. 79:181–211. 2010.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Moynahan ME and Jasin M: Mitotic
homologous recombination maintains genomic stability and suppresses
tumorigenesis. Nat Rev Mol Cell Biol. 11:196–207. 2010.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Khan AQ, Travers JB and Kemp MG: Roles of
UVA radiation and DNA damage responses in melanoma pathogenesis.
Environ Mol Mutagen. 59:438–460. 2018.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Schlacher K, Wu H and Jasin M: A distinct
replication fork protection pathway connects Fanconi anemia tumor
suppressors to RAD51-BRCA1/2. Cancer Cell. 22:106–116.
2012.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Murai J, Huang SY, Das BB, Renaud A, Zhang
Y, Doroshow JH, Ji J, Takeda S and Pommier Y: Trapping of PARP1 and
PARP2 by clinical PARP inhibitors. Cancer Res. 72:5588–5599.
2012.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Fong PC, Boss DS, Yap TA, Tutt A, Wu P,
Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, et
al: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA
mutation carriers. N Engl J Med. 361:123–134. 2009.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Palma JP, Rodriguez LE, Bontcheva-Diaz VD,
Bouska JJ, Bukofzer G, Colon-Lopez M, Guan R, Jarvis K, Johnson EF,
Klinghofer V, et al: The PARP inhibitor, ABT-888 potentiates
temozolomide: Correlation with drug levels and reduction in PARP
activity in vivo. Anticancer Res. 28:2625–2635. 2008.PubMed/NCBI
|
|
54
|
Plummer R, Lorigan P, Steven N, Scott L,
Middleton MR, Wilson RH, Mulligan E, Curtin N, Wang D, Dewji R, et
al: A phase II study of the potent PARP inhibitor, Rucaparib
(PF-01367338, AG014699), with temozolomide in patients with
metastatic melanoma demonstrating evidence of chemopotentiation.
Cancer Chemother Pharmacol. 71:1191–1199. 2013.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Middleton MR, Friedlander P, Hamid O, Daud
A, Plummer R, Falotico N, Chyla B, Jiang F, McKeegan E, Mostafa NM,
et al: Randomized phase II study evaluating veliparib (ABT-888)
with temozolomide in patients with metastatic melanoma. Ann Oncol.
26:2173–2179. 2015.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Lau B, Menzies AM and Joshua AM: Ongoing
partial response at 6 months to olaparib for metastatic melanoma
with somatic PALB2 mutation after failure of immunotherapy: A case
report. Ann Oncol. 32:280–282. 2021.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Khaddour K, Ansstas M and Ansstas G:
Clinical outcomes and longitudinal circulating tumor DNA changes
after treatment with nivolumab and olaparib in immunotherapy
relapsed melanoma with detected homologous recombination
deficiency. Cold Spring Harb Mol Case Stud.
7(a006129)2021.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Fratangelo F, Camerlingo R, Carriero MV,
Pirozzi G, Palmieri G, Gentilcore G, Ragone C, Minopoli M, Ascierto
PA and Motti ML: Effect of ABT-888 on the apoptosis, motility and
invasiveness of BRAFi-resistant melanoma cells. Int J Oncol.
53:1149–1159. 2018.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Giunta EF, Belli V, Napolitano S, De Falco
V, Vitiello PP, Terminiello M, Caputo V, Vitale P, Zanaletti N,
Ciardiello D, et al: 13P Synergistic activity of PARP inhibitor and
ATR inhibitor in melanoma cell lines may depend on BRAF-V600
mutation status. Ann Oncol. 31:S248–S2S9. 2020.
|
|
60
|
Folkman J: Tumor angiogenesis: Therapeutic
implications. N Engl J Med. 285:1182–1186. 1971.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Ye W: The complexity of translating
Anti-angiogenesis therapy from basic science to the clinic. Dev
Cell. 37:114–125. 2016.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Claesson-Welsh L and Welsh M: VEGFA and
tumour angiogenesis. J Intern Med. 273:114–127. 2013.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Kim KB, Sosman JA, Fruehauf JP, Linette
GP, Markovic SN, McDermott DF, Weber JS, Nguyen H, Cheverton P,
Chen D, et al: BEAM: A randomized phase II study evaluating the
activity of bevacizumab in combination with carboplatin plus
paclitaxel in patients with previously untreated advanced melanoma.
J Clin Oncol. 30:34–41. 2012.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Ferrucci PF, Minchella I, Mosconi M,
Gandini S, Verrecchia F, Cocorocchio E, Passoni C, Pari C, Testori
A, Coco P and Munzone E: Dacarbazine in combination with
bevacizumab for the treatment of unresectable/metastatic melanoma:
A phase II study. Melanoma Res. 25:239–245. 2015.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Del Vecchio M, Mortarini R, Canova S, Di
Guardo L, Pimpinelli N, Sertoli MR, Bedognetti D, Queirolo P,
Morosini P, Perrone T, et al: Bevacizumab plus fotemustine as
first-line treatment in metastatic melanoma patients: Clinical
activity and modulation of angiogenesis and lymphangiogenesis
factors. Clin Cancer Res. 16:5862–5872. 2010.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Yan X, Sheng X, Chi Z, Si L, Cui C, Kong
Y, Tang B, Mao L, Wang X, Lian B, et al: Randomized phase II study
of bevacizumab in combination with carboplatin plus paclitaxel in
patients with previously untreated advanced mucosal melanoma. J
Clin Oncol. 39:881–889. 2021.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Zhou J, Mahoney KM, Giobbie-Hurder A, Zhao
F, Lee S, Liao X, Rodig S, Li J, Wu X, Butterfield LH, et al:
Soluble PD-L1 as a biomarker in malignant melanoma treated with
checkpoint blockade. Cancer Immunol Res. 5:480–492. 2017.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Algazi AP, Cha E, Ortiz-Urda SM, McCalmont
T, Bastian BC, Hwang J, Pampaloni MH, Behr S, Chong K, Cortez B, et
al: The combination of axitinib followed by paclitaxel/carboplatin
yields extended survival in advanced BRAF wild-type melanoma:
Results of a clinical/correlative prospective phase II clinical
trial. Br J Cancer. 112:1326–1331. 2015.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Fruehauf J, Lutzky J, McDermott D, Brown
CK, Meric JB, Rosbrook B, Shalinsky DR, Liau KF, Niethammer AG, Kim
S and Rixe O: Multicenter, phase II study of axitinib, a selective
second-generation inhibitor of vascular endothelial growth factor
receptors 1, 2, and 3, in patients with metastatic melanoma. Clin
Cancer Res. 17:7462–7469. 2011.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Mouriaux F, Servois V, Parienti JJ,
Lesimple T, Thyss A, Dutriaux C, Neidhart-Berard EM, Penel N,
Delcambre C, Peyro Saint Paul L, et al: Sorafenib in metastatic
uveal melanoma: Efficacy, toxicity and health-related quality of
life in a multicentre phase II study. Br J Cancer. 115:20–24.
2016.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Sheng X, Cao D, Yuan J, Zhou F, Wei Q, Xie
X, Cui C, Chi Z, Si L, Li S, et al: Sorafenib in combination with
gemcitabine plus cisplatin chemotherapy in metastatic renal
collecting duct carcinoma: A prospective, multicentre, single-arm,
phase 2 study. Eur J Cancer. 100:1–7. 2018.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Buchbinder EI, Sosman JA, Lawrence DP,
McDermott DF, Ramaiya NH, Van den Abbeele AD, Linette GP,
Giobbie-Hurder A and Hodi FS: Phase 2 study of sunitinib in
patients with metastatic mucosal or acral melanoma. Cancer.
121:4007–4015. 2015.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Mahalingam D, Malik L, Beeram M, Rodon J,
Sankhala K, Mita A, Benjamin D, Ketchum N, Michalek J, Tolcher A,
et al: Phase II study evaluating the efficacy, safety, and
pharmacodynamic correlative study of dual antiangiogenic inhibition
using bevacizumab in combination with sorafenib in patients with
advanced malignant melanoma. Cancer Chemother Pharmacol. 74:77–84.
2014.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Mittal K, Koon H, Elson P, Triozzi P,
Dowlati A, Chen H, Borden EC and Rini BI: Dual VEGF/VEGFR
inhibition in advanced solid malignancies: Clinical effects and
pharmacodynamic biomarkers. Cancer Biol Ther. 15:975–981.
2014.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Carlino MS, Todd JR and Rizos H:
Resistance to c-Kit inhibitors in melanoma: Insights for future
therapies. Oncoscience. 1:423–426. 2014.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Curtin JA, Busam K, Pinkel D and Bastian
BC: Somatic activation of KIT in distinct subtypes of melanoma. J
Clin Oncol. 24:4340–4346. 2006.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Guo J, Si L, Kong Y, Flaherty KT, Xu X,
Zhu Y, Corless CL, Li L, Li H, Sheng X, et al: Phase II,
open-label, single-arm trial of imatinib mesylate in patients with
metastatic melanoma harboring c-Kit mutation or amplification. J
Clin Oncol. 29:2904–2909. 2011.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Jung S, Armstrong E, Wei AZ, Ye F, Lee A,
Carlino MS, Sullivan RJ, Carvajal RD, Shoushtari AN and Johnson DB:
Clinical and genomic correlates of imatinib response in melanomas
with KIT alterations. Br J Cancer. 127:1726–1732. 2022.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Lee SJ, Kim TM, Kim YJ, Jang KT, Lee HJ,
Lee SN, Ahn MS, Hwang IG, Lee S, Lee MH and Lee J: Phase II trial
of nilotinib in patients with metastatic malignant melanoma
Harboring KIT gene aberration: A multicenter trial of Korean cancer
study group (UN10-06). Oncologist. 20:1312–1319. 2015.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Guo J, Carvajal RD, Dummer R, Hauschild A,
Daud A, Bastian BC, Markovic SN, Queirolo P, Arance A, Berking C,
et al: Efficacy and safety of nilotinib in patients with
KIT-mutated metastatic or inoperable melanoma: Final results from
the global, single-arm, phase II TEAM trial. Ann Oncol.
28:1380–1387. 2017.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Delyon J, Chevret S, Jouary T, Dalac S,
Dalle S, Guillot B, Arnault JP, Avril MF, Bedane C, Bens G, et al:
STAT3 mediates nilotinib response in KIT-altered melanoma: A phase
II multicenter trial of the french skin cancer network. J Invest
Dermatol. 138:58–67. 2018.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Cho JH, Kim KM, Kwon M, Kim JH and Lee J:
Nilotinib in patients with metastatic melanoma harboring KIT gene
aberration. Invest New Drugs. 30:2008–2014. 2012.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Carvajal RD, Lawrence DP, Weber JS,
Gajewski TF, Gonzalez R, Lutzky J, O'Day SJ, Hamid O, Wolchok JD,
Chapman PB, et al: Phase II study of nilotinib in melanoma
Harboring KIT alterations following progression to prior KIT
inhibition. Clin Cancer Res. 21:2289–2296. 2015.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Hodi FS, Corless CL, Giobbie-Hurder A,
Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R,
Weber JS, Gajewski TF, et al: Imatinib for melanomas harboring
mutationally activated or amplified KIT arising on mucosal, acral,
and chronically sun-damaged skin. J Clin Oncol. 31:3182–3190.
2013.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Saxton RA and Sabatini DM: mTOR signaling
in growth, metabolism, and disease. Cell. 169:361–371.
2017.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Karbowniczek M, Spittle CS, Morrison T, Wu
H and Henske EP: mTOR is activated in the majority of malignant
melanomas. J Invest Dermatol. 128:980–987. 2008.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Slingluff CL Jr, Petroni GR, Molhoek KR,
Brautigan DL, Chianese-Bullock KA, Shada AL, Smolkin ME, Olson WC,
Gaucher A, Chase CM, et al: Clinical activity and safety of
combination therapy with temsirolimus and bevacizumab for advanced
melanoma: A phase II trial (CTEP 7190/Mel47). Clin Cancer Res.
19:3611–3620. 2013.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Hainsworth JD, Infante JR, Spigel DR,
Peyton JD, Thompson DS, Lane CM, Clark BL, Rubin MS, Trent DF and
Burris HA III: Bevacizumab and everolimus in the treatment of
patients with metastatic melanoma: A phase 2 trial of the Sarah
Cannon Oncology Research Consortium. Cancer. 116:4122–4129.
2010.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Krummel MF and Allison JP: CD28 and CTLA-4
have opposing effects on the response of T cells to stimulation. J
Exp Med. 182:459–465. 1995.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Chen DS, Irving BA and Hodi FS: Molecular
pathways: Next-generation immunotherapy-inhibiting programmed
death-ligand 1 and programmed death-1. Clin Cancer Res.
18:6580–6587. 2012.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Leach DR, Krummel MF and Allison JP:
Enhancement of antitumor immunity by CTLA-4 blockade. Science.
271:1734–1736. 1996.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Okazaki T, Iwai Y and Honjo T: New
regulatory co-receptors: Inducible co-stimulator and PD-1. Curr
Opin Immunol. 14:779–782. 2002.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Hodi FS, O'Day SJ, McDermott DF, Weber RW,
Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel
JC, et al: Improved survival with ipilimumab in patients with
metastatic melanoma. N Engl J Med. 363:711–723. 2010.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Eggermont AM, Chiarion-Sileni V, Grob JJ,
Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA,
Richards JM, et al: Prolonged survival in stage III melanoma with
ipilimumab adjuvant therapy. N Engl J Med. 375:1845–1855.
2016.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Eggermont AM, Chiarion-Sileni V, Grob JJ,
Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA,
Richards JM, et al: Adjuvant ipilimumab versus placebo after
complete resection of high-risk stage III melanoma (EORTC 18071): A
randomised, double-blind, phase 3 trial. Lancet Oncol. 16:522–530.
2015.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Bertrand A, Kostine M, Barnetche T,
Truchetet ME and Schaeverbeke T: Immune related adverse events
associated with anti-CTLA-4 antibodies: Systematic review and
meta-analysis. BMC Med. 13(211)2015.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Liao B, Shroff S, Kamiya-Matsuoka C and
Tummala S: Atypical neurological complications of ipilimumab
therapy in patients with metastatic melanoma. Neuro Oncol.
16:589–593. 2014.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Ribas A, Camacho LH, Lopez-Berestein G,
Pavlov D, Bulanhagui CA, Millham R, Comin-Anduix B, Reuben JM, Seja
E, Parker CA, et al: Antitumor activity in melanoma and anti-self
responses in a phase I trial with the anti-cytotoxic T
lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J
Clin Oncol. 23:8968–8977. 2005.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Kirkwood JM, Lorigan P, Hersey P,
Hauschild A, Robert C, McDermott D, Marshall MA, Gomez-Navarro J,
Liang JQ and Bulanhagui CA: Phase II trial of tremelimumab
(CP-675,206) in patients with advanced refractory or relapsed
melanoma. Clin Cancer Res. 16:1042–1048. 2010.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Ribas A, Kefford R, Marshall MA, Punt CJ,
Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, et
al: Phase III randomized clinical trial comparing tremelimumab with
standard-of-care chemotherapy in patients with advanced melanoma. J
Clin Oncol. 31:616–622. 2013.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Larkin J, Minor D, D'Angelo S, Neyns B,
Smylie M, Miller WH Jr, Gutzmer R, Linette G, Chmielowski B, Lao
CD, et al: Overall survival in patients with advanced melanoma who
received nivolumab versus Investigator's choice chemotherapy in
CheckMate 037: A randomized, controlled, open-label phase III
trial. J Clin Oncol. 36:383–390. 2018.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Ribas A, Puzanov I, Dummer R, Schadendorf
D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD,
et al: Pembrolizumab versus investigator-choice chemotherapy for
ipilimumab-refractory melanoma (KEYNOTE-002): A randomised,
controlled, phase 2 trial. Lancet Oncol. 16:908–918.
2015.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Ott PA, Hodi FS and Robert C: CTLA-4 and
PD-1/PD-L1 blockade: New immunotherapeutic modalities with durable
clinical benefit in melanoma patients. Clin Cancer Res.
19:5300–5309. 2013.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Hodi FS, Chesney J, Pavlick AC, Robert C,
Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK,
Agarwala SS, et al: Combined nivolumab and ipilimumab versus
ipilimumab alone in patients with advanced melanoma: 2-year overall
survival outcomes in a multicentre, randomised, controlled, phase 2
trial. Lancet Oncol. 17:1558–1568. 2016.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Wolchok JD, Chiarion-Sileni V, Gonzalez R,
Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J,
Dummer R, et al: Long-term outcomes with nivolumab plus ipilimumab
or nivolumab alone versus ipilimumab in patients with advanced
melanoma. J Clin Oncol. 40:127–137. 2022.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Larkin J, Chiarion-Sileni V, Gonzalez R,
Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J,
Dummer R, et al: Five-year survival with combined nivolumab and
ipilimumab in advanced melanoma. N Engl J Med. 381:1535–1546.
2019.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Long GV, Atkinson V, Lo S, Sandhu S,
Guminski AD, Brown MP, Wilmott JS, Edwards J, Gonzalez M, Scolyer
RA, et al: Combination nivolumab and ipilimumab or nivolumab alone
in melanoma brain metastases: A multicentre randomised phase 2
study. Lancet Oncol. 19:672–681. 2018.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Weber J, Mandala M, Del Vecchio M, Gogas
HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V,
Marquez-Rodas I, et al: Adjuvant Nivolumab versus ipilimumab in
resected stage III or IV melanoma. N Engl J Med. 377:1824–1835.
2017.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Larkin J, Del Vecchio M, Mandala M, Gogas
H, Arance AM, Dalle S, Cowey CL, Schenker M, Grob JJ,
Chiarion-Sileni V, et al: Adjuvant nivolumab versus ipilimumab in
resected stage III/IV melanoma: 5-year efficacy and biomarker
results from CheckMate 238. Clin Cancer Res: Apr 14, 2023 doi:
10.1158/1078-0432.CCR-22-3145 (Epub ahead of print).
|
|
110
|
Eggermont AMM, Blank CU, Mandala M, Long
GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A,
Carlino MS, et al: Longer Follow-up confirms recurrence-free
survival benefit of adjuvant pembrolizumab in high-risk stage III
melanoma: Updated results from the EORTC 1325-MG/KEYNOTE-054 trial.
J Clin Oncol. 38:3925–3936. 2020.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Eggermont AMM, Blank CU, Mandalà M, Long
GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A,
Carlino MS, et al: Adjuvant pembrolizumab versus placebo in
resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): Distant
metastasis-free survival results from a double-blind, randomised,
controlled, phase 3 trial. Lancet Oncol. 22:643–654.
2021.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Grossmann KF, Othus M, Patel SP, Tarhini
AA, Sondak VK, Knopp MV, Petrella TM, Truong TG, Khushalani NI,
Cohen JV, et al: Adjuvant pembrolizumab versus IFNα2b or ipilimumab
in resected high-risk melanoma. Cancer Discov. 12:644–653.
2022.PubMed/NCBI View Article : Google Scholar
|
|
113
|
Luke JJ, Rutkowski P, Queirolo P, Del
Vecchio M, Mackiewicz J, Chiarion-Sileni V, de la Cruz Merino L,
Khattak MA, Schadendorf D, Long GV, et al: Pembrolizumab versus
placebo as adjuvant therapy in completely resected stage IIB or IIC
melanoma (KEYNOTE-716): A randomised, double-blind, phase 3 trial.
Lancet. 399:1718–1729. 2022.PubMed/NCBI View Article : Google Scholar
|
|
114
|
Lao CD, Khushalani NI, Angeles C and
Petrella TM: Current state of adjuvant therapy for melanoma: Less
is more, or more is better? Am Soc Clin Oncol Educ Book. 42:1–7.
2022.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Blank CU, Rozeman EA, Fanchi LF, Sikorska
K, van de Wiel B, Kvistborg P, Krijgsman O, van den Braber M,
Philips D, Broeks A, et al: Neoadjuvant versus adjuvant ipilimumab
plus nivolumab in macroscopic stage III melanoma. Nat Med.
24:1655–1661. 2018.PubMed/NCBI View Article : Google Scholar
|
|
116
|
Rozeman EA, Menzies AM, van Akkooi ACJ,
Adhikari C, Bierman C, van de Wiel BA, Scolyer RA, Krijgsman O,
Sikorska K, Eriksson H, et al: Identification of the optimal
combination dosing schedule of neoadjuvant ipilimumab plus
nivolumab in macroscopic stage III melanoma (OpACIN-neo): A
multicentre, phase 2, randomised, controlled trial. Lancet Oncol.
20:948–960. 2019.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Rozeman EA, Hoefsmit EP, Reijers ILM, Saw
RPM, Versluis JM, Krijgsman O, Dimitriadis P, Sikorska K, van de
Wiel BA, Eriksson H, et al: Survival and biomarker analyses from
the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage
III melanoma. Nat Med. 27:256–263. 2021.PubMed/NCBI View Article : Google Scholar
|
|
118
|
Versluis JM, Menzies AM, Sikorska K,
Rozeman EA, Saw RPM, van Houdt WJ, Eriksson H, Klop WMC, Ch'ng S,
van Thienen JV, et al: Survival update of neoadjuvant ipilimumab
plus nivolumab in macroscopic stage III melanoma in the OpACIN and
OpACIN-neo trials. Ann Oncol. 34:420–430. 2023.PubMed/NCBI View Article : Google Scholar
|
|
119
|
Reijers ILM, Menzies AM, van Akkooi ACJ,
Versluis JM, van den Heuvel NMJ, Saw RPM, Pennington TE, Kapiteijn
E, van der Veldt AAM, Suijkerbuijk KPM, et al: Personalized
response-directed surgery and adjuvant therapy after neoadjuvant
ipilimumab and nivolumab in high-risk stage III melanoma: The PRADO
trial. Nat Med. 28:1178–1188. 2022.PubMed/NCBI View Article : Google Scholar
|
|
120
|
Long GV, Menzies AM and Scolyer RA:
Neoadjuvant checkpoint immunotherapy and melanoma: The time is now.
J Clin Oncol. 41:3236–3248. 2023.PubMed/NCBI View Article : Google Scholar
|
|
121
|
Lucas M, Lijnsvelt J, Pulleman S, Scolyer
RA, Menzies AM, Van Akkooi ACJ, van Houdt WJ, Shannon KF,
Pennington T, Suijkerbuijk K, et al: The NADINA trial: A
multicenter, randomised, phase 3 trial comparing the efficacy of
neoadjuvant ipilimumab plus nivolumab with standard adjuvant
nivolumab in macroscopic resectable stage III melanoma. J Clin
Oncol. 40(TPS9605)2022.
|
|
122
|
Qin S, Xu L, Yi M, Yu S, Wu K and Luo S:
Novel immune checkpoint targets: Moving beyond PD-1 and CTLA-4. Mol
Cancer. 18(155)2019.PubMed/NCBI View Article : Google Scholar
|
|
123
|
Woo SR, Turnis ME, Goldberg MV, Bankoti J,
Selby M, Nirschl CJ, Bettini ML, Gravano DM, Vogel P, Liu CL, et
al: Immune inhibitory molecules LAG-3 and PD-1 synergistically
regulate T-cell function to promote tumoral immune escape. Cancer
Res. 72:917–927. 2012.PubMed/NCBI View Article : Google Scholar
|
|
124
|
Ascierto PA, Bono P, Bhatia S, Melero I,
Nyakas MS, Svane IM, Gomez-Roca C, Larkin J, Schadendorf D, Dummer
R, et al: LBA18 Efficacy of BMS-986016, a monoclonal antibody that
targets lymphocyte activation gene-3 (LAG-3), in combination with
nivolumab in pts with melanoma who progressed during prior
anti–PD-1/PD-L1 therapy (mel prior IO) in all-comer and
biomarker-enriched populations. Ann Oncol. 28:611–612. 2017.
|
|
125
|
Tawbi HA, Schadendorf D, Lipson EJ,
Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas
HJ, Lao CD, De Menezes JJ, et al: Relatlimab and nivolumab versus
nivolumab in untreated advanced melanoma. N Engl J Med. 386:24–34.
2022.PubMed/NCBI View Article : Google Scholar
|
|
126
|
Amaria RN, Postow M, Burton EM, Tetzlaff
MT, Ross MI, Torres-Cabala C, Glitza IC, Duan F, Milton DR, Busam
K, et al: Neoadjuvant relatlimab and nivolumab in resectable
melanoma. Nature. 611:155–160. 2022.PubMed/NCBI View Article : Google Scholar
|
|
127
|
Rosenberg SA, Lotze MT, Muul LM, Leitman
S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E,
Vetto JT, et al: Observations on the systemic administration of
autologous lymphokine-activated killer cells and recombinant
interleukin-2 to patients with metastatic cancer. N Engl J Med.
313:1485–1492. 1985.PubMed/NCBI View Article : Google Scholar
|
|
128
|
Rosenberg SA, Spiess P and Lafreniere R: A
new approach to the adoptive immunotherapy of cancer with
tumor-infiltrating lymphocytes. Science. 233:1318–1321.
1986.PubMed/NCBI View Article : Google Scholar
|
|
129
|
Rosenberg SA, Yang JC, Sherry RM, Kammula
US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF,
Wunderlich JR, et al: Durable complete responses in heavily
pretreated patients with metastatic melanoma using T-cell transfer
immunotherapy. Clin Cancer Res. 17:4550–4557. 2011.PubMed/NCBI View Article : Google Scholar
|
|
130
|
Sarnaik AA, Hamid O, Khushalani NI, Lewis
KD, Medina T, Kluger HM, Thomas SS, Domingo-Musibay E, Pavlick AC,
Whitman ED, et al: Lifileucel, a Tumor-infiltrating lymphocyte
therapy, in metastatic melanoma. J Clin Oncol. 39:2656–2666.
2021.PubMed/NCBI View Article : Google Scholar
|
|
131
|
Seitter SJ, Sherry RM, Yang JC, Robbins
PF, Shindorf ML, Copeland AR, McGowan CT, Epstein M, Shelton TE,
Langhan MM, et al: Impact of prior treatment on the efficacy of
adoptive transfer of tumor-infiltrating lymphocytes in patients
with metastatic melanoma. Clin Cancer Res. 27:5289–5298.
2021.PubMed/NCBI View Article : Google Scholar
|
|
132
|
Sarnaik AA, Hamid O, Khushalani NI, Lewis
KD, Medina T, Kluger HM, Thomas SS, Domingo-Musibay E, Pavlick AC,
Whitman ED, et al: Lifileucel, a Tumor-infiltrating lymphocyte
therapy, in metastatic melanoma. J Clin Oncol. 39:2656–2666.
2021.PubMed/NCBI View Article : Google Scholar
|
|
133
|
Larkin J, Sarnaik A, Chesney JA,
Khushalani NI, Kirkwood JM, Weber JS, Lewis KD, Medina TM, Kluger
HM, Thomas SS, et al: Lifileucel (LN-144), a cryopreserved
autologous tumor infiltrating lymphocyte (TIL) therapy in patients
with advanced melanoma: Evaluation of impact of prior anti-PD-1
therapy. J Clin Oncol. 39 (15_suppl)(9505)2021.
|
|
134
|
David OM, Sylvia L, Amanda P, Sukari A,
Thomas S, Wenham R, Gogas H, Jazaeri A, Monk B, Rose P, et al: 492
Phase 2 efficacy and safety of autologous tumor-infiltrating
lymphocyte (TIL) cell therapy in combination with pembrolizumab in
immune checkpoint inhibitor-naïve patients with advanced cancers. J
Immuno Therapy Cancer. 9 (Suppl 2)(A523)2021.
|
|
135
|
Puzanov I, Milhem MM, Minor D, Hamid O, Li
A, Chen L, Chastain M, Gorski KS, Anderson A, Chou J, et al:
Talimogene laherparepvec in combination with ipilimumab in
previously untreated, unresectable stage IIIB-IV melanoma. J Clin
Oncol. 34:2619–2626. 2016.PubMed/NCBI View Article : Google Scholar
|
|
136
|
Long G, Dummer R, Johnson D, Michielin O,
Martin-Algarra S, Treichel S, Chan E, Diede S and Ribas A: 429
Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene
laherparepvec (T-VEC) plus pembrolizumab in patients with
unresectable stage IIIB-IVM1c melanoma. J ImmunoTherapy Cancer. 8
(Suppl 3)(A261)2020.
|
|
137
|
Chesney J, Puzanov I, Collichio F, Singh
P, Milhem MM, Glaspy J, Hamid O, Ross M, Friedlander P, Garbe C, et
al: Randomized, Open-label phase II study evaluating the efficacy
and safety of talimogene laherparepvec in combination with
ipilimumab versus ipilimumab alone in patients with advanced,
unresectable melanoma. J Clin Oncol. 36:1658–1667. 2018.PubMed/NCBI View Article : Google Scholar
|
|
138
|
Chesney JA, Ribas A, Long GV, Kirkwood JM,
Dummer R, Puzanov I, Hoeller C, Gajewski TF, Gutzmer R, Rutkowski
P, et al: Randomized, Double-blind, placebo-controlled, global
phase III trial of talimogene laherparepvec combined with
pembrolizumab for advanced melanoma. J Clin Oncol. 41:528–540.
2022.PubMed/NCBI View Article : Google Scholar
|
|
139
|
Lowe KL, Cole D, Kenefeck R, I OK, Lepore
M and Jakobsen BK: Novel TCR-based biologics: Mobilising T cells to
warm ‘cold’ tumours. Cancer Treat Rev. 77:35–43. 2019.PubMed/NCBI View Article : Google Scholar
|
|
140
|
Oates J, Hassan NJ and Jakobsen BK:
ImmTACs for targeted cancer therapy: Why, what, how, and which. Mol
Immunol. 67:67–74. 2015.PubMed/NCBI View Article : Google Scholar
|
|
141
|
Carvajal RD, Nathan P, Sacco JJ, Orloff M,
Hernandez-Aya LF, Yang J, Luke JJ, Butler MO, Stanhope S, Collins
L, et al: Phase I study of safety, tolerability, and efficacy of
tebentafusp using a Step-up dosing regimen and expansion in
patients with metastatic uveal melanoma. J Clin Oncol.
40:1939–1948. 2022.PubMed/NCBI View Article : Google Scholar
|
|
142
|
Nathan P, Hassel JC, Rutkowski P, Baurain
JF, Butler MO, Schlaak M, Sullivan RJ, Ochsenreither S, Dummer R,
Kirkwood JM, et al: Overall survival benefit with tebentafusp in
metastatic uveal melanoma. N Engl J Med. 385:1196–1206.
2021.PubMed/NCBI View Article : Google Scholar
|
|
143
|
Piulats JM, Espinosa E, de la Cruz Merino
L, Varela M, Alonso Carrión L, Martín-Algarra S, López Castro R,
Curiel T, Rodríguez-Abreu D, Redrado M, et al: Nivolumab plus
ipilimumab for treatment-naïve metastatic uveal melanoma: An
open-label, multicenter, phase II trial by the spanish
multidisciplinary melanoma group (GEM-1402). J Clin Oncol.
39:586–598. 2021.PubMed/NCBI View Article : Google Scholar
|
|
144
|
Pelster MS, Gruschkus SK, Bassett R,
Gombos DS, Shephard M, Posada L, Glover MS, Simien R, Diab A, Hwu
P, et al: Nivolumab and ipilimumab in metastatic uveal melanoma:
Results from a single-arm phase II study. J Clin Oncol. 39:599–607.
2021.PubMed/NCBI View Article : Google Scholar
|
|
145
|
Carlino MS, Larkin J and Long GV: Immune
checkpoint inhibitors in melanoma. Lancet. 398:1002–1014.
2021.PubMed/NCBI View Article : Google Scholar
|
|
146
|
Begley J and Ribas A: Targeted therapies
to improve tumor immunotherapy. Clin Cancer Res. 14:4385–4391.
2008.PubMed/NCBI View Article : Google Scholar
|
|
147
|
Koya RC, Mok S, Otte N, Blacketor KJ,
Comin-Anduix B, Tumeh PC, Minasyan A, Graham NA, Graeber TG, Chodon
T and Ribas A: BRAF inhibitor vemurafenib improves the antitumor
activity of adoptive cell immunotherapy. Cancer Res. 72:3928–3937.
2012.PubMed/NCBI View Article : Google Scholar
|
|
148
|
Wilmott JS, Long GV, Howle JR, Haydu LE,
Sharma RN, Thompson JF, Kefford RF, Hersey P and Scolyer RA:
Selective BRAF inhibitors induce marked T-cell infiltration into
human metastatic melanoma. Clin Cancer Res. 18:1386–1394.
2012.PubMed/NCBI View Article : Google Scholar
|
|
149
|
Frederick DT, Piris A, Cogdill AP, Cooper
ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, et
al: BRAF inhibition is associated with enhanced melanoma antigen
expression and a more favorable tumor microenvironment in patients
with metastatic melanoma. Clin Cancer Res. 19:1225–1231.
2013.PubMed/NCBI View Article : Google Scholar
|
|
150
|
Boni A, Cogdill AP, Dang P, Udayakumar D,
Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, Lawrence DP, Fisher
DE, et al: Selective BRAFV600E inhibition enhances T-cell
recognition of melanoma without affecting lymphocyte function.
Cancer Res. 70:5213–5219. 2010.PubMed/NCBI View Article : Google Scholar
|
|
151
|
Ribas A, Lawrence D, Atkinson V, Agarwal
S, Miller WH Jr, Carlino MS, Fisher R, Long GV, Hodi FS, Tsoi J, et
al: Combined BRAF and MEK inhibition with PD-1 blockade
immunotherapy in BRAF-mutant melanoma. Nat Med. 25:936–940.
2019.PubMed/NCBI View Article : Google Scholar
|
|
152
|
Ascierto PA, Ferrucci PF, Fisher R, Del
Vecchio M, Atkinson V, Schmidt H, Schachter J, Queirolo P, Long GV,
Di Giacomo AM, et al: Dabrafenib, trametinib and pembrolizumab or
placebo in BRAF-mutant melanoma. Nat Med. 25:941–946.
2019.PubMed/NCBI View Article : Google Scholar
|
|
153
|
Ferrucci PF, Di Giacomo AM, Del Vecchio M,
Atkinson V, Schmidt H, Schachter J, Queirolo P, Long GV, Stephens
R, Svane IM, et al: KEYNOTE-022 part 3: A randomized, double-blind,
phase 2 study of pembrolizumab, dabrafenib, and trametinib in
BRAF-mutant melanoma. J Immunother Cancer.
8(e001806)2020.PubMed/NCBI View Article : Google Scholar
|
|
154
|
Maio M, Carlino MS, Joshua AM, McWhirter
E, Ribas A, Ascierto PA, Miller WH Jr, Butler MO, Ferrucci PF,
Zielinski RR, et al: KEYNOTE-022: Pembrolizumab with trametinib in
patients with BRAF wild-type melanoma or advanced solid tumours
irrespective of BRAF mutation. Eur J Cancer. 160:1–11.
2022.PubMed/NCBI View Article : Google Scholar
|
|
155
|
Dummer R, Lebbé C, Atkinson V, Mandalà M,
Nathan PD, Arance A, Richtig E, Yamazaki N, Robert C, Schadendorf
D, et al: Combined PD-1, BRAF and MEK inhibition in advanced
BRAF-mutant melanoma: Safety run-in and biomarker cohorts of
COMBI-i. Nat Med. 26:1557–1563. 2020.PubMed/NCBI View Article : Google Scholar
|
|
156
|
Tawbi HA, Robert C, Brase JC, Gusenleitner
D, Gasal E, Garrett J, Savchenko A, Görgün G, Flaherty KT, Ribas A,
et al: Spartalizumab or placebo in combination with dabrafenib and
trametinib in patients with BRAF V600-mutant melanoma: Exploratory
biomarker analyses from a randomized phase 3 trial (COMBI-i). J
Immunother Cancer. 10(e004226)2022.PubMed/NCBI View Article : Google Scholar
|
|
157
|
Johnson DB, Pectasides E, Feld E, Ye F,
Zhao S, Johnpulle R, Merritt R, McDermott DF, Puzanov I, Lawrence
D, et al: Sequencing treatment in BRAFV600 mutant melanoma:
Anti-PD-1 before and after BRAF inhibition. J Immunother. 40:31–35.
2017.PubMed/NCBI View Article : Google Scholar
|
|
158
|
Saab KR, Mooradian MJ, Wang DY, Chon J,
Xia CY, Bialczak A, Abbate KT, Menzies AM, Johnson DB, Sullivan RJ
and Shoushtari AN: Tolerance and efficacy of BRAF plus MEK
inhibition in patients with melanoma who previously have received
programmed cell death protein 1-based therapy. Cancer. 125:884–891.
2019.PubMed/NCBI View Article : Google Scholar
|
|
159
|
Atkins MB, Lee SJ, Chmielowski B, Tarhini
AA, Cohen GI, Truong TG, Moon HH, Davar D, O'Rourke M, Stephenson
JJ, et al: Combination dabrafenib and trametinib versus combination
nivolumab and ipilimumab for patients with advanced BRAF-mutant
melanoma: The DREAMseq trial-ECOG-ACRIN EA6134. J Clin Oncol.
41:186–197. 2023.PubMed/NCBI View Article : Google Scholar
|
|
160
|
Ascierto PA, Mandalà M, Ferrucci PF,
Guidoboni M, Rutkowski P, Ferraresi V, Arance A, Guida M, Maiello
E, Gogas H, et al: Sequencing of ipilimumab plus nivolumab and
encorafenib plus binimetinib for untreated BRAF-mutated metastatic
melanoma (SECOMBIT): A randomized, Three-arm, Open-label phase II
Trial. J Clin Oncol. 41:212–221. 2023.PubMed/NCBI View Article : Google Scholar
|
|
161
|
Ziogas DC, Theocharopoulos C, Koutouratsas
T, Haanen J and Gogas H: Mechanisms of resistance to immune
checkpoint inhibitors in melanoma: What we have to overcome? Cancer
Treat Rev. 113(102499)2023.PubMed/NCBI View Article : Google Scholar
|
|
162
|
Schmittnaegel M, Rigamonti N, Kadioglu E,
Cassará A, Wyser Rmili C, Kiialainen A, Kienast Y, Mueller HJ, Ooi
CH, Laoui D and De Palma M: Dual angiopoietin-2 and VEGFA
inhibition elicits antitumor immunity that is enhanced by PD-1
checkpoint blockade. Sci Transl Med. 9(eaak9670)2017.PubMed/NCBI View Article : Google Scholar
|
|
163
|
Schoenfeld J, Jinushi M, Nakazaki Y,
Wiener D, Park J, Soiffer R, Neuberg D, Mihm M, Hodi FS and Dranoff
G: Active immunotherapy induces antibody responses that target
tumor angiogenesis. Cancer Res. 70:10150–10160. 2010.PubMed/NCBI View Article : Google Scholar
|
|
164
|
Yi M, Jiao D, Qin S, Chu Q, Wu K and Li A:
Synergistic effect of immune checkpoint blockade and
anti-angiogenesis in cancer treatment. Mol Cancer.
18(60)2019.PubMed/NCBI View Article : Google Scholar
|
|
165
|
Chen PL, Roh W, Reuben A, Cooper ZA,
Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V,
Wani K, et al: Analysis of immune signatures in longitudinal tumor
samples yields insight into biomarkers of response and mechanisms
of resistance to immune checkpoint blockade. Cancer Discov.
6:827–837. 2016.PubMed/NCBI View Article : Google Scholar
|
|
166
|
Adachi Y, Kamiyama H, Ichikawa K,
Fukushima S, Ozawa Y, Yamaguchi S, Goda S, Kimura T, Kodama K,
Matsuki M, et al: Inhibition of FGFR reactivates IFNγ signaling in
tumor cells to enhance the combined antitumor activity of
lenvatinib with Anti-PD-1 antibodies. Cancer Res. 82:292–306.
2022.PubMed/NCBI View Article : Google Scholar
|
|
167
|
Kato Y, Tabata K, Kimura T,
Yachie-Kinoshita A, Ozawa Y, Yamada K, Ito J, Tachino S, Hori Y,
Matsuki M, et al: Lenvatinib plus anti-PD-1 antibody combination
treatment activates CD8+ T cells through reduction of
tumor-associated macrophage and activation of the interferon
pathway. PLoS One. 14(e0212513)2019.PubMed/NCBI View Article : Google Scholar
|
|
168
|
O'Day S, Gonzalez R, Kim K, Chmielowski B,
Kefford R, Loquai GLC, Cowey CL, Hauschild A, Hainsworth JD, Hersey
P, et al: A phase II study of the multitargeted kinase inhibitor
lenvatinib in patients with advanced BRAF wild-type melanoma. J
Clin Oncol. 31(9026)2013.
|
|
169
|
Taylor MH, Lee CH, Makker V, Rasco D,
Dutcus CE, Wu J, Stepan DE, Shumaker RC and Motzer RJ: Phase IB/II
trial of lenvatinib plus pembrolizumab in patients with advanced
renal cell carcinoma, endometrial cancer, and other selected
advanced solid tumors. J Clin Oncol. 38:1154–1163. 2020.PubMed/NCBI View Article : Google Scholar
|
|
170
|
Arance A, de la Cruz-Merino L, Petrella
TM, Jamal R, Ny L, Carneiro A, Berrocal A, Márquez-Rodas I,
Spreafico A, Atkinson V, et al: Phase II LEAP-004 study of
lenvatinib plus pembrolizumab for melanoma with confirmed
progression on a programmed cell death Protein-1 or programmed
death ligand 1 inhibitor given as monotherapy or in combination. J
Clin Oncol. 41:75–85. 2023.PubMed/NCBI View Article : Google Scholar
|
|
171
|
Tarhini AA, Frankel P, Margolin KA,
Christensen S, Ruel C, Shipe-Spotloe J, Gandara DR, Chen A and
Kirkwood JM: Aflibercept (VEGF Trap) in inoperable stage III or
stage IV melanoma of cutaneous or uveal origin. Clin Cancer Res.
17:6574–6581. 2011.PubMed/NCBI View Article : Google Scholar
|
|
172
|
Strickland KC, Howitt BE, Shukla SA, Rodig
S, Ritterhouse LL, Liu JF, Garber JE, Chowdhury D, Wu CJ, D'Andrea
AD, et al: Association and prognostic significance of
BRCA1/2-mutation status with neoantigen load, number of
tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high
grade serous ovarian cancer. Oncotarget. 7:13587–13598.
2016.PubMed/NCBI View Article : Google Scholar
|
|
173
|
Shen J, Zhao W, Ju Z, Wang L, Peng Y,
Labrie M, Yap TA, Mills GB and Peng G: PARPi Triggers the
STING-dependent immune response and enhances the therapeutic
efficacy of immune checkpoint blockade independent of BRCAness.
Cancer Res. 79:311–319. 2019.PubMed/NCBI View Article : Google Scholar
|
|
174
|
Jiao S, Xia W, Yamaguchi H, Wei Y, Chen
MK, Hsu JM, Hsu JL, Yu WH, Du Y, Lee HH, et al: PARP inhibitor
upregulates PD-L1 expression and enhances cancer-associated
immunosuppression. Clin Cancer Res. 23:3711–3720. 2017.PubMed/NCBI View Article : Google Scholar
|
|
175
|
Russo V and Protti MP: Tumor-derived
factors affecting immune cells. Cytokine Growth Factor Rev.
36:79–87. 2017.PubMed/NCBI View Article : Google Scholar
|
|
176
|
Showalter A, Limaye A, Oyer JL, Igarashi
R, Kittipatarin C, Copik AJ and Khaled AR: Cytokines in immunogenic
cell death: Applications for cancer immunotherapy. Cytokine.
97:123–132. 2017.PubMed/NCBI View Article : Google Scholar
|
|
177
|
Ribas A, Medina T, Kummar S, Amin A,
Kalbasi A, Drabick JJ, Barve M, Daniels GA, Wong DJ, Schmidt EV, et
al: SD-101 in combination with pembrolizumab in advanced melanoma:
Results of a phase Ib, multicenter study. Cancer Discov.
8:1250–1257. 2018.PubMed/NCBI View Article : Google Scholar
|
|
178
|
Ribas A, Medina T, Kirkwood JM, Zakharia
Y, Gonzalez R, Davar D, Chmielowski B, Campbell KM, Bao R, Kelley
H, et al: Overcoming PD-1 Blockade resistance with CpG-A toll-like
receptor 9 agonist vidutolimod in patients with metastatic
melanoma. Cancer Discov. 11:2998–3007. 2021.PubMed/NCBI View Article : Google Scholar
|
|
179
|
Matson V, Chervin CS and Gajewski TF:
Cancer and the Microbiome-influence of the commensal microbiota on
cancer, immune responses, and immunotherapy. Gastroenterology.
160:600–613. 2021.PubMed/NCBI View Article : Google Scholar
|
|
180
|
Routy B, Le Chatelier E, Derosa L, Duong
CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C,
Roberti MP, et al: Gut microbiome influences efficacy of PD-1-based
immunotherapy against epithelial tumors. Science. 359:91–97.
2018.PubMed/NCBI View Article : Google Scholar
|
|
181
|
Matson V, Fessler J, Bao R, Chongsuwat T,
Zha Y, Alegre ML, Luke JJ and Gajewski TF: The commensal microbiome
is associated with anti-PD-1 efficacy in metastatic melanoma
patients. Science. 359:104–108. 2018.PubMed/NCBI View Article : Google Scholar
|
|
182
|
Davar D, Dzutsev AK, McCulloch JA,
Rodrigues RR, Chauvin JM, Morrison RM, Deblasio RN, Menna C, Ding
Q, Pagliano O, et al: Fecal microbiota transplant overcomes
resistance to anti-PD-1 therapy in melanoma patients. Science.
371:595–602. 2021.PubMed/NCBI View Article : Google Scholar
|
|
183
|
Gok Yavuz B, Gunaydin G, Gedik ME,
Kosemehmetoglu K, Karakoc D, Ozgur F and Guc D: Cancer associated
fibroblasts sculpt tumour microenvironment by recruiting monocytes
and inducing immunosuppressive PD-1+ TAMs. Sci Rep.
9(3172)2019.PubMed/NCBI View Article : Google Scholar
|
|
184
|
Baruch EN, Youngster I, Ben-Betzalel G,
Ortenberg R, Lahat A, Katz L, Adler K, Dick-Necula D, Raskin S,
Bloch N, et al: Fecal microbiota transplant promotes response in
immunotherapy-refractory melanoma patients. Science. 371:602–609.
2021.PubMed/NCBI View Article : Google Scholar
|
|
185
|
Carreira S, Goodall J, Denat L, Rodriguez
M, Nuciforo P, Hoek KS, Testori A, Larue L and Goding CR: Mitf
regulation of Dia1 controls melanoma proliferation and
invasiveness. Genes Dev. 20:3426–3439. 2006.PubMed/NCBI View Article : Google Scholar
|
|
186
|
Arozarena I and Wellbrock C: Phenotype
plasticity as enabler of melanoma progression and therapy
resistance. Nat Rev Cancer. 19:377–391. 2019.PubMed/NCBI View Article : Google Scholar
|
|
187
|
Smith MP, Brunton H, Rowling EJ, Ferguson
J, Arozarena I, Miskolczi Z, Lee JL, Girotti MR, Marais R, Levesque
MP, et al: Inhibiting drivers of non-mutational drug tolerance is a
salvage strategy for targeted melanoma therapy. Cancer Cell.
29:270–284. 2016.PubMed/NCBI View Article : Google Scholar
|
|
188
|
Haq R, Yokoyama S, Hawryluk EB, Jönsson
GB, Frederick DT, McHenry K, Porter D, Tran TN, Love KT, Langer R,
et al: BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene
that confers resistance to BRAF inhibition. Proc Natl Acad Sci USA.
110:4321–4326. 2013.PubMed/NCBI View Article : Google Scholar
|
|
189
|
Smith MP, Sanchez-Laorden B, O'Brien K,
Brunton H, Ferguson J, Young H, Dhomen N, Flaherty KT, Frederick
DT, Cooper ZA, et al: The immune microenvironment confers
resistance to MAPK pathway inhibitors through macrophage-derived
TNFα. Cancer Discov. 4:1214–1229. 2014.PubMed/NCBI View Article : Google Scholar
|
|
190
|
Müller J, Krijgsman O, Tsoi J, Robert L,
Hugo W, Song C, Kong X, Possik PA, Cornelissen-Steijger PD, Geukes
Foppen MH, et al: Low MITF/AXL ratio predicts early resistance to
multiple targeted drugs in melanoma. Nat Commun.
5(5712)2014.PubMed/NCBI View Article : Google Scholar
|
|
191
|
Nyakas M, Fleten KG, Haugen MH, Engedal N,
Sveen C, Farstad IN, Flørenes VA, Prasmickaite L, Mælandsmo GM and
Seip K: AXL inhibition improves BRAF-targeted treatment in
melanoma. Sci Rep. 12(5076)2022.PubMed/NCBI View Article : Google Scholar
|
|
192
|
Lee JH, Shklovskaya E, Lim SY, Carlino MS,
Menzies AM, Stewart A, Pedersen B, Irvine M, Alavi S, Yang JYH, et
al: Transcriptional downregulation of MHC class I and melanoma
de-differentiation in resistance to PD-1 inhibition. Nat Commun.
11(1897)2020.PubMed/NCBI View Article : Google Scholar
|
|
193
|
Falcone I, Conciatori F, Bazzichetto C,
Ferretti G, Cognetti F, Ciuffreda L and Milella M: Tumor
microenvironment: Implications in melanoma resistance to targeted
therapy and immunotherapy. Cancers (Basel). 12(2870)2020.PubMed/NCBI View Article : Google Scholar
|
